Search

Corona virus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome corona virus 2 (SARSCoV2) and has currently affected 11 million people worldwide with 0.53 million deaths. While there is ongoing trials and research for newer therapeutic options including antivirals (remdesivir), anti-interleukin 6 (tocilizumab), vaccines and antimalarials; there is renewed interest in the use of old therapeutic tools as well. Convalescent plasma has been used historically for measles, poliomyelitis, Spanish flu pandemic, severe acute respiratory syndrome (SARS1) and Ebola epidemics with conflicting results. With widespread use of convalescent plasma throughout the world as investigational drug for COVID-19, it is important to review past experience with its use in various outbreaks, potential role in COVID-19, and clinical application during current pandemic and challenges faced by resource constrained countries. [ABSTRACT FROM AUTHOR]

Fanconi anemia (FA) is a rare, genetically and phenotypically heterogeneous autosomal recessive disorder. It is characterized by various congenital malformations, progressive bone marrow failure usually at a very young age and of tumor development. The mean age of diagnosis was 7 years and the average life expectancy was 25 years. We report a rare case of fanconi anemia presenting as a solid tumor of buccal cavity and found to be metastasizing on staging at an unusually late age i.e. 52 years. [ABSTRACT FROM AUTHOR]